JCB, Volume 17, Number 4, 2011 Editorial Vol.17 No. 4 (2011) Exciting changes Yali Friedman Commentary Vol.17 No. 4 (2011) New technologies for neglected diseases: Can tax credits help biotechnology companies advance global health? Aarthi Rao Biotechnology companies can play an important role in advancing technologies for global health. Initiatives such as Genzyme's Humanitarian Assistance for Neglected Diseases Commentary Vol.17 No. 4 (2011) Biotechnology commercialisation in universities of developing countries: A review of the University of Ibadan, Nigeria Chimdiya Julian Onyeka The British colonial administration established the University of Ibadan (UI) in 1948 as an extension of the University College London and it became Nigeria's first full-fl Article Vol.17 No. 4 (2011) Innovation in R&D: Using design thinking to develop new models of inventiveness, productivity and collaboration Tad Simons By adapting insights and methodologies from design thinking, a modern scientific R&D organization may have the potential to increase the speed, inventiveness and vi Article Vol.17 No. 4 (2011) The strength of pharmaceutical IPRs vis-à -vis foreign direct investment in clinical research: Preliminary findings Meir Perez Pugatch This article examines the effect of the intellectual property (IP) environment in developing countries on the level of foreign direct investment (FDI) and technology tr Article Vol.17 No. 4 (2011) Some considerations for the implementation of disposable technology and single-use systems in biopharmaceuticals Tim Sandle This article, written from an industry perspective, examines the current trend towards the implementation of single-use disposable technologies in the biopharmaceutical Article Vol.17 No. 4 (2011) Catalyzing capital for Canada's life sciences industry Joseph Tucker Canada's biotech sector ranks within the top five globally, but its life sciences venture capital (VC) industry is among the worlds weakest. This makes for an interesti Article Vol.17 No. 4 (2011) Academic entrepreneurship, entrepreneurial universities and biotechnology Arlen D Meyers There are various definitions of an entrepreneurial university, yet there is a lack of agreement about its core components. This article defines the five key characteri Legal and Regulatory Updates Vol.17 No. 4 (2011) Patent strategies for life sciences companies to navigate the changing patent landscape David J Dykeman As a result of the global recession that began in 2008, life sciences companies face a groundswell of new business and regulatory pressures that includes health care and pa Conference Report Vol.17 No. 4 (2011) FDA at BIO 2011 – Weighing a hefty mission: Where is the balance? Suzanne Levy The mission of the Food and Drug Administration (FDA) is to promote public health by ensuring the safety and quality of food and medical products sold in the United States.